# Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

> **NCT07674524** · — · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 160 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)
- Hyperlipidemia
- ALK Gene Mutation
- ALK-positive

## Interventions

- **DRUG:** For Part A - Observational Cohort:
- **DRUG:** Part B: Intensive Lipid-Lowering Group
- **DRUG:** For Part B - Intensive Group

## Key facts

- **NCT ID:** NCT07674524
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674524, "Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07674524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*